Both conferences will provide a venue to meet with investors, partnering prospects and biotechnology industry participants. This year Company’s Earnings per Share (EPS) growth is 21.90% and next year’s EPS growth is -7.10%.
Advertisement
Shares of the company registered a buying and selling volume of 4.66 million shares lower than its 3-months average volume of 6.92 million shares and traded in range of $15.06 to $16.21.
The mean price target for the stock is set at $46.67 and the upmost price target recommended by the analysts is $49while also low price target recorded at $44. Taking a peek at where the stock might be headed in the future, analysts have a consensus target price of $19.23 on the stock. Return on equity (ROE) was noted as -141.30% while return on investment (ROI) was -103.00%. Sarepta is obtaining the data from two muscle biopsies taken from each of 13 boys being treated with eteplirsen right now as part of the ongoing phase III study known as “Promovi”. Sarepta plans to submit data from 13 patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.
“The Peripheral and Central Nervous System Advisory Committee met last week to review eteplirsen for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping, and we await our May 26 PDUFA date”, said Edward Kaye, M.D., Sarepta’s interim chief executive officer and chief medical officer. This focus has only increased after BioMarin, another company in the space, announced it would halt current development of DMD drugs and withdraw an application for European approval of its main drug drisapersen.
Shares of Immunomedics, Inc. The shares were acquired at an average price of $14.54 per share, with a total value of $145,400.00. The stock is presently trading 2.37% above from its SMA-50. Stock institutional ownership is 15.60% while insider ownership includes 38.50%. A look on the firm performance, its monthly performance is -4.24% and a quarterly performance of 12.32%. Additionally, its median price target is stands at $47. Proceeds will be used for liability management and general corporate purposes. IFP Advisors Inc boosted its position in Juno Therapeutics by 103.5% in the first quarter.
Shares of Carbylan Therapeutics Inc (NASDAQ:CBYL) ended Friday session in green amid volatile trading. Using the Prime Now mobile app or by visiting the new Prime Now website, Miami customers can view participating restaurants, browse menus, place orders, track the status of their delivery, and watch as their delivery driver travels from the restaurant to the delivery address in real time.
Advertisement
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases.
